TY - JOUR
T1 - Microdissection-Based Genotyping Assists Discrimination of Reactive Gliosis from Glioma
AU - Finkelstein, Sydney D.
AU - Mohan, Deepak
AU - Hamilton, Ronald L.
AU - Sasatomi, Eizaburo
AU - Swalsky, Patricia A.
AU - Lieberman, Frank S.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2004/5
Y1 - 2004/5
N2 - We used molecular anatomic pathology to determine the mutational status (loss of heterozygosity [LOH]) to make the distinction between reactive gliosis and glial neoplasia. LOH has been shown to be absent in reactive states and present in neoplastic cellular proliferations. Three groups of patient specimens were analyzed: group 1, reactive gliosis (n = 15); group 2, gliomas of varying histologic type and grade (n = 54); group 3, diagnostically challenging reactive gliosis vs glioma (n = 16). No group 1 cases (0/15 [0%]) showed allelic loss, whereas all high-grade glial neoplasms, a subset of group 2 (35/35 [100%]) manifested at least 1 allelic loss alteration, with most cases (33/35 [94%]) displaying 2 or more such changes. During a look forward at the group 3 patients, clinical history clarified the problematic diagnosis in a subset of 11 patients: 8 (73%) of 11 clinical outcomes were predicted correctly by our analysis. The molecular anatomic pathology approach outlined herein is designed for minute, formalin-fixed, paraffin-embedded specimens, which are encountered in everyday surgical pathology practice. Molecular anatomic pathology opens the possibilities of molecular analysis to everyday pathology practice.
AB - We used molecular anatomic pathology to determine the mutational status (loss of heterozygosity [LOH]) to make the distinction between reactive gliosis and glial neoplasia. LOH has been shown to be absent in reactive states and present in neoplastic cellular proliferations. Three groups of patient specimens were analyzed: group 1, reactive gliosis (n = 15); group 2, gliomas of varying histologic type and grade (n = 54); group 3, diagnostically challenging reactive gliosis vs glioma (n = 16). No group 1 cases (0/15 [0%]) showed allelic loss, whereas all high-grade glial neoplasms, a subset of group 2 (35/35 [100%]) manifested at least 1 allelic loss alteration, with most cases (33/35 [94%]) displaying 2 or more such changes. During a look forward at the group 3 patients, clinical history clarified the problematic diagnosis in a subset of 11 patients: 8 (73%) of 11 clinical outcomes were predicted correctly by our analysis. The molecular anatomic pathology approach outlined herein is designed for minute, formalin-fixed, paraffin-embedded specimens, which are encountered in everyday surgical pathology practice. Molecular anatomic pathology opens the possibilities of molecular analysis to everyday pathology practice.
KW - Glioma
KW - Gliosis
KW - LOH
KW - Loss of heterozygosity
KW - Microdissection
KW - Molecular anatomic pathology
KW - Molecular genotyping
KW - Mutation
KW - PCR
KW - Polymerase chain reaction
UR - http://www.scopus.com/inward/record.url?scp=2042460882&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2042460882&partnerID=8YFLogxK
U2 - 10.1309/WF2HL03T7YP713NK
DO - 10.1309/WF2HL03T7YP713NK
M3 - Article
C2 - 15151207
AN - SCOPUS:2042460882
SN - 0002-9173
VL - 121
SP - 671
EP - 678
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 5
ER -